Economic evaluation of six and 12 month (m) treatment with isatuximab and carfilzomib and dexamethasone (IKd) versus daratumumab and carfilzomib and dexamethasone (DKd) in patients with relapsed or refractory multiple myeloma (RRMM).

Neda AlRawashdh,Briana Choi,Mavis Obeng-Kusi,Matthias Calamia,Ali McBride,Ivo Abraham

Economic evaluation of six and 12 month (m) treatment with isatuximab and carfilzomib and dexamethasone (IKd) versus daratumumab and carfilzomib and dexamethasone (DKd) in patients with relapsed or refractory multiple myeloma (RRMM).

2021

Neda AlRawashdh
Briana Choi
Mavis Obeng-Kusi
Matthias Calamia
Ali McBride
Ivo Abraham

e20010Background: Isatuximab and daratumumab target the CD38 transmembrane glycoprotein on MM cells. IKd and DKd regimens have shown reductions of HR=0.53 (95%CI 0.32-0.89) and HR=0.63 (95%CI 0.46-...

Keywords:

Transmembrane glycoprotein
Internal medicine
Medicine
Carfilzomib
CD38
in patient
Oncology
Isatuximab
Daratumumab
Dexamethasone
Refractory Multiple Myeloma

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations